Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Authors
Keywords
-
Journal
Molecular Oncology
Volume 6, Issue 2, Pages 155-176
Publisher
Wiley
Online
2012-03-06
DOI
10.1016/j.molonc.2012.02.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lead-Oriented Synthesis: A New Opportunity for Synthetic Chemistry
- (2012) Alan Nadin et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
- (2012) Sachin Surade et al. CHEMISTRY & BIOLOGY
- Drug Development: Portals of Discovery
- (2012) S. E. Bates et al. CLINICAL CANCER RESEARCH
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
- (2012) L. Neckers et al. CLINICAL CANCER RESEARCH
- The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities
- (2012) Michele De Palma et al. Molecular Oncology
- Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
- (2012) Natasha M. DeVore et al. NATURE
- Clonal evolution in cancer
- (2012) Mel Greaves et al. NATURE
- Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
- (2011) Timothy A. Yap et al. Annual Review of Pharmacology and Toxicology
- The rise and fall of gatekeeper mutations? TheBCR-ABL1T315I paradigm
- (2011) Don L. Gibbons et al. CANCER
- Unswitch-ABL Drugs Overcome Resistance in Chronic Myeloid Leukemia
- (2011) Leisl Packer et al. CANCER CELL
- Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
- (2011) Wayne W. Chan et al. CANCER CELL
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- A Blueprint for Advancing Genetics-Based Cancer Therapy
- (2011) William R. Sellers CELL
- Genetic Interactions in Cancer Progression and Treatment
- (2011) Alan Ashworth et al. CELL
- A molecular informatics view on best practice in multi-parameter compound optimization
- (2011) Scott J. Lusher et al. DRUG DISCOVERY TODAY
- Follow-on drugs: How far should chemists look?
- (2011) Fabrizio Giordanetto et al. DRUG DISCOVERY TODAY
- Hypothesis driven drug design: improving quality and effectiveness of the design-make-test-analyse cycle
- (2011) Alleyn T. Plowright et al. DRUG DISCOVERY TODAY
- New regulatory framework for cancer drug development
- (2011) Paul S. Jones et al. DRUG DISCOVERY TODAY
- HSP90 inhibition: two-pronged exploitation of cancer dependencies
- (2011) Jon Travers et al. DRUG DISCOVERY TODAY
- How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers
- (2011) Katerina Politi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphatidylinositide-3-Kinase Inhibitors: Addressing Questions of Isoform Selectivity and Pharmacodynamic/Predictive Biomarkers in Early Clinical Trials
- (2011) Paul A. Clarke et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Getting pharmaceutical R&D back on target
- (2011) Mark E Bunnage Nature Chemical Biology
- Improving the efficacy of translational medicine by optimally integrating health care, academia and industry
- (2011) Stefan R Bornstein et al. NATURE MEDICINE
- Advances in the preclinical testing of cancer therapeutic hypotheses
- (2011) Giordano Caponigro et al. NATURE REVIEWS DRUG DISCOVERY
- Impact of high-throughput screening in biomedical research
- (2011) Ricardo Macarron et al. NATURE REVIEWS DRUG DISCOVERY
- The resurgence of covalent drugs
- (2011) Juswinder Singh et al. NATURE REVIEWS DRUG DISCOVERY
- Believe it or not: how much can we rely on published data on potential drug targets?
- (2011) Florian Prinz et al. NATURE REVIEWS DRUG DISCOVERY
- Towards systematic functional characterization of cancer genomes
- (2011) Jesse S. Boehm et al. NATURE REVIEWS GENETICS
- Genomics and the Continuum of Cancer Care
- (2011) Ultan McDermott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- canSAR: an integrated cancer public translational research and drug discovery resource
- (2011) Mark D. Halling-Brown et al. NUCLEIC ACIDS RESEARCH
- Exploring the Genomes of Cancer Cells: Progress and Promise
- (2011) M. R. Stratton SCIENCE
- Molecular obesity, potency and other addictions in drug discovery
- (2011) Michael M. Hann MedChemComm
- Functional Viability Profiles of Breast Cancer
- (2011) R. Brough et al. Cancer Discovery
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- Transcript Profiling and RNA Interference as Tools To Identify Small Molecule Mechanisms and Therapeutic Potential
- (2010) Rahul Palchaudhuri et al. ACS Chemical Biology
- Vigilance and Validation: Keys to Success in RNAi Screening
- (2010) Frederic D. Sigoillot et al. ACS Chemical Biology
- Genomic Screening with RNAi: Results and Challenges
- (2010) Stephanie Mohr et al. Annual Review of Biochemistry
- High-throughput RNAi screening to dissect cellular pathways: A how-to guide
- (2010) Christina Falschlehner et al. Biotechnology Journal
- Guidelines for the welfare and use of animals in cancer research
- (2010) P Workman et al. BRITISH JOURNAL OF CANCER
- Biomarker-Driven Early Clinical Trials in Oncology
- (2010) Daniel S. W. Tan et al. CANCER JOURNAL
- Biochemical Target Isolation for Novices: Affinity-Based Strategies
- (2010) Shin-ichi Sato et al. CHEMISTRY & BIOLOGY
- Probing the Probes: Fitness Factors For Small Molecule Tools
- (2010) Paul Workman et al. CHEMISTRY & BIOLOGY
- Cheminformatics approaches to analyze diversity in compound screening libraries
- (2010) Lakshmi B Akella et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Apparent activity in high-throughput screening: origins of compound-dependent assay interference
- (2010) Natasha Thorne et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Evolving molecules using multi-objective optimization: applying to ADME/Tox
- (2010) Sean Ekins et al. DRUG DISCOVERY TODAY
- Clinical Implications of the Cancer Genome
- (2010) Laura E. MacConaill et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
- (2010) Jonathan B. Baell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Quo Vadis, Virtual Screening? A Comprehensive Survey of Prospective Applications
- (2010) Peter Ripphausen et al. JOURNAL OF MEDICINAL CHEMISTRY
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Translating cancer research into targeted therapeutics
- (2010) J. S. de Bono et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Preclinical development of molecular-targeted agents for cancer
- (2010) Alberto Ocana et al. Nature Reviews Clinical Oncology
- Competitiveness in follow-on drug R&D: a race or imitation?
- (2010) Joseph A. DiMasi et al. NATURE REVIEWS DRUG DISCOVERY
- How to improve R&D productivity: the pharmaceutical industry's grand challenge
- (2010) Steven M. Paul et al. NATURE REVIEWS DRUG DISCOVERY
- Virtual screening: an endless staircase?
- (2010) Gisbert Schneider NATURE REVIEWS DRUG DISCOVERY
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
- (2010) Wen-I Wu et al. PLoS One
- GDC-0449—A potent inhibitor of the hedgehog pathway
- (2009) Kirk D. Robarge et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
- (2009) Ji Luo et al. CELL
- RNA interference screening for the discovery of oncology targets
- (2009) Kim Quon et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone
- (2009) Paul A. Brough et al. JOURNAL OF MEDICINAL CHEMISTRY
- Covalent Modifiers: An Orthogonal Approach to Drug Design
- (2009) Michele H. Potashman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
- (2009) F. I. Raynaud et al. MOLECULAR CANCER THERAPEUTICS
- Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
- (2009) Shih-Min A. Huang et al. NATURE
- Inhibitor hijacking of Akt activation
- (2009) Tatsuya Okuzumi et al. Nature Chemical Biology
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trapping Moving Targets with Small Molecules
- (2009) G. M. Lee et al. SCIENCE
- Physiochemical drug properties associated with in vivo toxicological outcomes
- (2008) Jason D. Hughes et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib
- (2008) T. M. Gilmer et al. CANCER RESEARCH
- Oncogene Addiction
- (2008) I. B. Weinstein et al. CANCER RESEARCH
- Targeted therapy for cancer using PARP inhibitors
- (2008) Christopher J Lord et al. CURRENT OPINION IN PHARMACOLOGY
- Predicting druggable binding sites at the protein–protein interface
- (2008) Jonathan C. Fuller et al. DRUG DISCOVERY TODAY
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Beyond Picomolar Affinities: Quantitative Aspects of Noncovalent and Covalent Binding of Drugs to Proteins
- (2008) Adam J. T. Smith et al. JOURNAL OF MEDICINAL CHEMISTRY
- Paul Ehrlich: founder of chemotherapy
- (2008) Stefan H. E. Kaufmann NATURE REVIEWS DRUG DISCOVERY
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Extracting kinetic rate constants from surface plasmon resonance array systems
- (2007) Rebecca L. Rich et al. ANALYTICAL BIOCHEMISTRY
- 4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer
- (2007) Paul A. Brough et al. JOURNAL OF MEDICINAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started